Congratulations to HTFL’s Client Boustead Securities, LLC on Closing Soliton, Inc.’s IPO of USD$10.4 Million
February 19, 2019
This Valentine’s Day, our client Boustead Securities, LLC, acting as the sole underwriter, completed the initial public offering (the “Offering”) of Soliton, Inc. (the "Company") a pre-revenue stage medical device company with a proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center. The Company raised approximately $10.4 million in gross proceeds from this initial closing, before deducting underwriting commissions and other offering expenses, by issuing 2,086,391 ordinary shares at a public offering price of $5.00 per share. Soliton has been approved to begin trading its shares on the Nasdaq Capital Market under the symbol ”SOLY” on Tuesday February 19, 2019. The Offering is the first IPO using Tier II of Regulation A to be completed on Nasdaq or NYSE in over one year.
